Osteoporosis
144 results
1 - 100
Guidelines for osteoporosis screening (USPSTF)- Treatment of osteoporosis is not associated with increased longevity
- ACP clinical guidelines for osteoporosis treatment
- MORES risk estimation tool for male osteoporosis screening
- Soy supplements do not affect menopause or osteoporosis
- ACR guideline for managing patients with glucocorticoid-induced osteoporosis
- Zoledronic acid reduces fracture risk in osteoporosis, osteopenia with previous fracture
- Teriparatide questionably better than alendronate in treating steroid-induced osteoporosis
- American College of Rheumatology guideline for preventing and treating steroid-induced osteoporosis
- Osteoporosis screening in older women: fewer hip fractures but no overall reduction in fractures
- Romosozumab prevents clinical fracture slightly better than alendronate in women with osteoporosis and previous fracture
- USPSTF 2025 recommends screening to prevent osteoporotic fractures in women 65 years and older (B recommendation)
- USPSTF 2018 recommends screening to prevent osteoporotic fractures in women 65 years and older (B recommendation)
- Parathyroid hormone prevents recurrent fractures
- No need to monitor BMD after bisphosphonates started
- Alendronate therapy unnecessary for most women after 5 years
- Most women quickly stop taking bisphosphonates
- Vitamin D, at high doses, prevents fractures
- Zoledronic acid reduces asymptomatic fractures but not clinical ones in men
- Tibolone prevents osteoporotic fracture, increases stroke risk (LIFT)
- Denosumab reduces fracture risk better than placebo (FREEDOM)
- Bisphosphonates decrease vertebral fractures but not clinically important fractures in men
- Denosumab no better than bisphosphonates at preventing fracture, and the cost is much higher
- Oral bisphosphonate use not associated with increased risk of esophageal cancer
- Reduced all-cause mortality associated with post-fracture bisphosphonate treatment